openPR Logo
Press release

Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

04-19-2017 05:57 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Malaria Vaccines Market - Global Industry Insights, Trends,

Malaria Vaccines Market Overview

More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest share of global malaria burden, with around 89% of malaria cases and 91% of malarial deaths in 2015. Such high impact of this life threatening disease is influencing governments across various countries, companies, investors, and non-profit organizations to contribute towards curbing spreading of this disease. Treatment therapies include Artemisinin-based combination therapies (ACTs), chloroquine, and primaquine. Recurrence of this disease can lead to drug resistance and in severe cases can prove fatal. Therefore, prevention is the major focus of government, researchers, and drug companies. The World Health Organization (WHO) estimates that increase in prevention control and other measures has led to 60% reduction in malaria mortality since 2000. High prevalence and preventive measures initiated by global and national organizations would favor growth of the global malaria vaccines market.

Mosquirix – the First Malaria Vaccine in the Global Malaria Vaccines Market

Most major drug manufacturers have been constantly striving to develop a vaccine for this deadly disease. Among the pioneers in this field is GlaxoSmithKline, which has been working towards developing a malaria vaccine since 1984. In collaboration with the non-profit PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline developed the first malarial vaccine.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/37

Mosquirix, also known as RTS,S, was in development for around 30 years, with an investment of around US$ 565 million. Bill and Melinda Gates Foundation contributed over US$ 200 million towards this project. Mosquirix received marketing approval from the European authorities in July 2015. However, the WHO has recommended examination of the vaccine in a pilot study before introduction on a large scale. The study is being carried out in Africa, and has received a funding of US$ 25 million from Gavi—a global Vaccine Alliance—bringing together public and private sectors towards a common goal. Successful trials will lead to global launch of Mosquirix and boost the malaria vaccines market size.

Significant Potential for Malaria Vaccines Market in Africa, Latin America and Asia

Malaria vaccine seems to be the best solution to prevent the spread of malaria, especially considering increasing number of drug resistance cases and high fatality reported. People use bed nets and indoor residual spraying (IRS) to fight against mosquito infestation. Therefore, there is immense opportunity globally for malaria vaccines among the demographic group most at risk—infants (23 million births annually), pre-adolescent and early adolescent girls, pregnant women in sub-Saharan Africa, and population in Asia, Latin America, Africa, and Oceania. Furthermore, risk of transmission of the disease increases from the ‘traveller’ and military population travelling from the U.S., Europe, Japan, and Australia, a malaria free zone to the highly prone emerging economies. The global malaria vaccines market dynamics are mainly shaped by major purchasers, namely healthcare and non-profit organizations.

You can also get exclusive discount on this CMI report by clicking on this link: https://www.coherentmarketinsights.com/insight/request-discount/37

Malaria Vaccines Market Future Outlook

Mosquirix is a great boon for population in the highly prone regions of malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone emerging economies. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum that causes 95% of malaria cases. Mymetics Corporation—a Switzerland-based vaccines developer—uses its virosome platform technology to develop vaccines. There are two vaccine candidates in its pipeline, of which one cleared the phase 1b clinical trail, while the other is in the preclinical stage. Moreover, use of new technologies such as Nucleic acid vaccines, Proteosomes, and several new adjuvants could lead to development of next-generation malaria vaccines.

Such global commitments will encourage investors around the world to contribute towards a global malaria eradication mission. Further, the malaria vaccines market outlook for future holds much promise, with new vaccines being developed mainly focused on improving effectiveness of products.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/malaria-vaccines-market-37

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #320000A0
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: http://healthcaremarketconsulting.blogspot.in/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024 here

News-ID: 506874 • Views:

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic foot ulcers treatment market
Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017 – 2025
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2025 globally
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Malaria

Industry Dynamics of Cerebral Malaria Therapeutics
Global Cerebral Malaria Therapeutics Market: Overview Cerebral malaria, a severe neuropathological complication, primarily caused by Plasmodium falciparum. The infectious disease has become prevalent in tropical and sub-tropical countries. The cerebral malaria therapeutics market has evolved on the back of increased understanding of pathogenesis of the neurological syndrome. A growing array of biomarkers and tool in recent years have helped underpin the growing revenue potential in the market, giving rise to numerous
Malaria Vaccines – Paving the Way for a Malaria-free World
Recent Study on “Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis and Forecast, 2018-2026” Added to Coherent Market Insights Reports Database. Malaria Vaccines Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Malaria Vaccines market research report is a professional
Malaria Disease Drug Pipeline Analysis
“Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Malaria. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug
Rising Prevalence of Cerebral Malaria and Increasing Novel Drug Treatment Drives …
Malaria is a mosquito-borne infectious disease affecting humans and animals caused by parasitic protozoan belonging to the plasmodium family. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Severe malaria can cause yellow skin, seizures, coma, or death. Cerebral malaria is a form of severe malaria. Cerebral malaria has
03-08-2017 | Health & Medicine
TMR
Rising Prevalence of Cerebral Malaria and Increasing Novel Drug Treatment Drives …
Malaria is a mosquito-borne infectious disease affecting humans and animals caused by parasitic protozoan belonging to the plasmodium family. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Severe malaria can cause yellow skin, seizures, coma, or death. Cerebral malaria is a form of severe malaria. Cerebral malaria has
Malaria Diagnostics Market : Future Growth Potential Of The Malaria Diagnostic & …
Malaria is caused by the Plasmodium parasite, which is transmitted by the female Anopheles mosquito. As per the WHO, there were around 203 mn cases of malaria worldwide in 2012, resulting in approximately 627,000 deaths. The diagnosis of malaria involves detection with the help of blood tests and microscopy. Early and accurate diagnosis of malaria is vital for the rapid recovery of the patient and this has raised investments in